ClinicalTrials.gg
CompletedNCT06347900Updated May 2, 2025

Corneal Topographic Changes in Different Grades of OSA

An observational study in Corneal Ectasia, sponsored by Sohag University. Completed at 1 site in Egypt. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by Sohag University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
60
Ages
20 Years to 50 Years
Sex
All
01

Study summary

Corneal topographic parameters in different degrees of obstructive sleep apnea

Read the detailed description

Obstructive sleep apnea (OSA) syndrome is a disease characterized by recurrent total or partial upper airway collapse during sleep, interrupting or reducing the airflow, and after ward resulting in temporary awakening which causes restoration of flow of the upper airway. These intermittent complete (apnea) or partial (hypopnea) respiratory cessations decrease blood oxygen levels (hypoxia).

Upper airway stenosis causes hypoxemia and hypercapnia, which can lead to multiple organ dysfunction and is associated with systemic diseases, such as hypertension, diabetes, and coronary arteriosclerosis, and changes in the eyes include floppy eyelid syndrome, keratoconus, and glaucoma.

The prevalence of OSA is between 2% and 10% in females and 4-20% in males and obesity is a major risk factor for the development of OSA.

With all the adverse effects associated with OSA, its secondary effects cause several ocular complications. Previous studies have shown that OSA is associated with increased risks of several vision-threatening and nonthreatening ocular disorders, including senile cataracts, normal-tension glaucoma, retinal ischemia, conjunctival hyperemia, and dry eye.

Several contributory mechanisms to the ocular complications of OSA have been reported, including intermittent hypoxia, oxidative stress, systemic inflammatory responses (such as interleukin-6 (IL-6), IL-8, tumor necrosis factor-alpha (TNF-α), C-Reactive protein (CRP), matrix metalloproteinase 9 (MMP-9), vascular cell adhesion molecule (VCAM), intercellular adhesion molecule (ICAM), selectins), sympathetic system overaction, damage effects of endothelin-1, and disruption of the blood-retinal barrier (BRB) (6-8). There are limited publications that manipulate the corneal topographic parameters in different degrees of OSA, especially in the Egyptian population.

02

Conditions studied

  • Corneal Ectasia
03

In context

Dilatation, Pathologic

120 studies on the registry are indexed under Dilatation, Pathologic; 18 are open to participants now.

This study's enrollment of 60 is below the median of 144 across 30 observational studies indexed under Dilatation, Pathologic.

Browse Dilatation, Pathologic studies →

Lead sponsor

Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

patients above age of 20 with obstructive sleep apnea syndrome with no history of previous ocular surgeries

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with diagnosed OSA

Exclusion criteria

Exclusion Criteria:

  • Any corneal scars, previous ocular surgeries, patients with keratoconus
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
60 participants (actual)
Patient registry
No

Groups and cohorts

  • Control group (Group1)

    Normal control subjects

    Diagnostic Test: Pentacam (corneal topographic changes detection), Polysymnography

  • Mild OSA (Group 2)

    Cases with mild obstructive sleep apnea (RDI) with respiratory distress index 5-15

    Diagnostic Test: Pentacam (corneal topographic changes detection), Polysymnography

  • Moderate OSA (Group 3)

    Cases with mild obstructive sleep apnea (RDI) with respiratory distress index 15-30

    Diagnostic Test: Pentacam (corneal topographic changes detection), Polysymnography

  • Sever OSA (Group4)

    Cases with mild obstructive sleep apnea (RDI) with respiratory distress index \>30

    Diagnostic Test: Pentacam (corneal topographic changes detection), Polysymnography

Interventions

  • Diagnostic testPentacam (corneal topographic changes detection), Polysymnography

    Pentacam for recording corneal parameters in different stages of OSA patients. Polysymnography for for detction of hyponea, oxygen saturation and desaturation and staging of OSA in different patients.

06

What researchers measure

Primary outcomes

  1. Keratometric readings in diopters, corneal thickness in um, average progression index value, anterior and posterior corneal elevation values.

    Keratometric readings in diopters, corneal thickness in um, average progression index value, anterior and posterior corneal elevation values.

    Time frame: 3 monthes

07

Study locations

1 site
  • Ophthalmology department, Sohag University
    Sohag, 82511, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06347900
Lead sponsor
Sohag University
Responsible party
Elshimaa A.Mateen (Clinical professor, Sohag University) — Principal investigator
First posted
Apr 4, 2024
Start date
Jan 1, 2024
Primary completion
Apr 30, 2024
Completion
Dec 30, 2024
Last update
May 2, 2025

Study contacts

Elshimaa A.Mateen
principal investigator · Assistant professor of ophthalmology, Sohag University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion